Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of BMS-599626 (AC480), an Oral Pan-HER Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Tumors

We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases.

Patients with advanced solid tumors that expressed epidermal growth factor receptor (EGFR) and/or HER-2 were recruited and enrolled in a phase I, open-label, dose escalation trial of oral BMS-599626 starting at 100 mg/day given once daily for at least 28 days.

Author(s): Jean-Charles Soria, Javier Cortés, Christophe Massard, Jean-Pierre Armand, Desiree De Andreis, Stanislas Ropert, Eva López, Aurélie Catteau, Joyce James, Jean-Francois Marier, Martin Beliveau, Robert Martell, José Baselga

Year: February 1, 2012